Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?

CureVac (NASDAQ: CVAC) recently announced that Boehringer Ingelheim terminated a partnership on a messenger RNA lung cancer vaccine program. In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not this canceled deal spells trouble for other mRNA cancer vaccines in development.

Continue reading

Source Fool.com